stoxline Quote Chart Rank Option Currency Glossary
Renovaro Biosciences Inc. (RENB)
3.49  0.13 (3.87%)    12-08 16:00
Open: 3.41
High: 3.55
Volume: 58,108
Pre. Close: 3.36
Low: 3.3976
Market Cap: 233(M)
Technical analysis
2023-12-08 4:45:43 PM
Short term     
Mid term     
Targets 6-month :  4.19 1-year :  4.9
Resists First :  3.59 Second :  4.19
Pivot price 3.23
Supports First :  2.97 Second :  2.58
MAs MA(5) :  3.36 MA(20) :  3.17
MA(100) :  2.81 MA(250) :  1.73
MACD MACD :  0 Signal :  0
%K %D K(14,3) :  77.1 D(3) :  72.2
RSI RSI(14): 59.3
52-week High :  5.25 Low :  0.39
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ RENB ] has closed below upper band by 16.5%. Bollinger Bands are 45.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 20 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 3.55 - 3.57 3.57 - 3.59
Low: 3.36 - 3.37 3.37 - 3.39
Close: 3.46 - 3.49 3.49 - 3.52
Company Description

Renovaro Biosciences Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company's product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV. It also develops RENB-DC-11, an allogeneic dendritic cell therapeutic vaccine for pancreatic cancer; RENB-DC-12-XX, an allogeneic dendritic cell therapeutic vaccine for other solid tumors; and RENB-HV-21 for treating HIV with allogeneic natural killer (NK) and gamma delta T-cells. It has strategic partnerships with the University of California, Fred Hutchinson Cancer Research Center, and Caring Cross. The company was formerly known as Enochian Biosciences, Inc. and changed its name to Renovaro Biosciences Inc. in August 2023. Renovaro Biosciences Inc. is headquartered in Los Angeles, California.

Headline News

Thu, 23 Nov 2023
Renovaro BioSciences Poised to Spearhead Advancements in Battle Against Diseases - Yahoo Finance

Tue, 21 Nov 2023
Renovaro BioSciences Eyes Opportunity in Precision Medicine Market - Yahoo Finance

Wed, 15 Nov 2023
Renovaro Biosciences: Fiscal Q1 Earnings Snapshot - Houston Chronicle

Wed, 15 Nov 2023
Renovaro Biosciences: Fiscal Q1 Earnings Snapshot | News | - The Bakersfield Californian

Tue, 10 Oct 2023
Renovaro Biosciences Appoints Two Finance Industry Experts to Board of Directors - GlobeNewswire

Mon, 02 Oct 2023
Message from Renovaro Biosciences CEO, The Hon. Mark Dybul, MD - GlobeNewswire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 67 (M)
Shares Float 30 (M)
Held by Insiders 59.5 (%)
Held by Institutions 5.7 (%)
Shares Short 638 (K)
Shares Short P.Month 644 (K)
Stock Financials
EPS -0.71
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.7
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -19 %
Return on Equity (ttm) -70.4 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -0.32
Qtrly Earnings Growth 0 %
Operating Cash Flow -12 (M)
Levered Free Cash Flow -6 (M)
Stock Valuations
PE Ratio -4.92
PEG Ratio 0
Price to Book value 4.91
Price to Sales 0
Price to Cash Flow -19.57
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android